APASL2016:在体内REP 2139-Ca和核苷（酸）类似物抗HBV治疗的抗病

StephenW

Antiviral effect of therapy with REP 2139-Ca and nucleos(t)ide analogues against HBV in vivo

Treatment of human patients with chronic HBV infection with the nucleic acid polymer (NAP) REP 2139 results in the elimination of circulating HBsAg. In this preclinical study we evaluated a novel combination therapy associating REP 2139-Ca with tenofovir diso- proxil fumarate (TDF) and entecavir (ETV), in vivo, in the DHBV infection model.
DHBV-carrier ducks were treated for 4 weeks with normal saline (IP), REP 2139-Ca (10 mg/kg IP QD), TDF (15 mg PO QD), REP 2139-Ca + TDF or REP 2139-Ca + TDF + ETV (1 mg PO QD). Serum DHBsAg was monitored by ELISA and DHBV DNA by qPCR. After therapy cessation all animals were followed during additional 8 weeks. Total DHBV DNA and cccDNA were analyzed in autopsy liver samples by qPCR.
On-treatment antiviral responses were more marked when REP 2139 was combined with TDF or TDF and ETV. Sustained virologic responses (SVR) during 2 months off-therapy were only observed in the groups receiving REP 2139 alone or in combination with TDF or TDF and ETV but not in TDF-monotherapy. SVR consisted of stably suppressed serum DHBsAg and DHBV DNA and significant decrease in liver DHBV DNA and cccDNA that were more marked in com- bination-therapy groups. Importantly, SVR animals had undetectable liver DHBsAg as assessed by immunostaining analysis.
Antiviral performance of REP 2139 was sustained and enhanced by combination with TDF or ETV. Thus an interferon-free regimen of REP 2139 with TDF or ETV could improve antiviral response and shorten treatment regimens in HBV infected patients. APASL2016:在体内REP 2139-Ca和核苷（酸）类似物抗HBV治疗的抗病毒作用

StephenW

在体内REP 2139-Ca和核苷（酸）类似物抗HBV治疗的抗病毒作用
人类慢性HBV感染与核酸聚合物（NAP）REP 2139的结果中消除循环的HBsAg的治疗。在此临床前研究中，我们评估了新的组合疗法REP 2139钙替诺福韦diso- proxil富马酸盐（TDF）和恩替卡韦（ETV）相关联，在体内，在DHBV感染模型。
DHBV载波鸭子4周用生理盐水（IP），REP 2139钙处理（10毫克/千克IP QD），TDF（15毫克PO QD），REP 2139钙+ TDF或REP 2139钙+ TDF + ETV（1毫克PO QD）。血清HBsAg通过ELISA和DHBV DNA通过qPCR监测。治疗停止后，所有动物在8周随访。总DHBV DNA和cccDNA的通过qPCR尸检肝样品中进行分析。
当REP 2139与TDF华盈或与ETV结合更标志着在治疗抗病毒反应。持续病毒学应答（SVR）在进行二数月的疗法的组分别只有观察到接收TDF-单一疗法REP 2139单独或与TDF或TDF与ETV组合，但并非如此。 SVR包括稳定抑制血清DHBsAg和乙型肝炎病毒DNA和肝DHBV DNA显著下降，cccDNA的是更为明显的COM bination，治疗组的的。重要的是，SVR动物检测不到肝DHBsAg通过免疫染色分析评估。
REP 2139的抗病毒性能持续用TDF或ETV组合增强。因此REP 2139与TDF或ETV的无干扰素疗法可以提高抗病毒反应，缩短乙肝病毒感染患者的治疗方案。

newchinabok

sw大神，你什么都好，就是太信rep，相信到迷信的程度，善良的愿望被一小绰坏人利用，欺骗

jinabest

回复 StephenW 的帖子

史蒂芬w大神，用你专业前沿的知识分析下，hbv离攻克究竟还有多远？究竟还有多难？如果运气好的最短时间，如果运气不好的最长时间。引力波都听到了，hbv难道比这还难？

StephenW

jinabest 发表于 2016-2-16 19:24
回复 StephenW 的帖子

史蒂芬w大神，用你专业前沿的知识分析下，hbv离攻克究竟还有多远？究竟还有多难？如 ...

我对我自己的的预测能力, 一点没有信心.
2010 APASL在北京, Replicor第一次发表了有关REP9AC的结果, 2016 APASL Replicor又发表了REP9AC的结果 - 感觉是deja vu.
短期内，没有神奇药，但也许有一个治愈方法.

wzu

大神，看错了，我以为大婶呢！老史到底男的女的啊？